Background: To describe the uptake and system-level effects of the introduction of biosimilars in a setting without forced switching.
Introduction
Since 1999, a growing number of biological disease modifying anti-rheumatic drugs (bDMARD) have been approved. Because of their effectiveness and high costs, their use has markedly changed the treatment landscape in rheumatology and similar therapeutic areas.
[1] Following patent expiration of several of the originator products, biosimilars have been introduced in clinical care. For regulatory approval, pharmacokinetics, pharmacodynamics and efficacy should be demonstrated to be comparable to the originator drug. [2] Because of the complex structure of bDMARDs, and the non-identical manufacturing processes for originator products and biosimilars, the market entry of biosimilars has been linked to concerns from patients and from their care-providers regarding their use in clinical practice. In particular, there is limited data on whether switching from an originator product to its biosimilar (the originator has reached its intended effect and the medical condition does not warrant replacement to a biosimilar, henceforth referred to as non-medical switch) can be made without loss of effectiveness or increased risk of adverse events.
Different countries have approached the introduction of biosimilars differently, in part reflecting the concerns above but mostly reflecting differences in tender and pricing policies, and in the individual prescribers' freedom in drug choice. [3, 4] Such differences may profoundly influence not only the uptake of biosimilars, but also the characteristics of patients selected for treatment with a biosimilar versus the originator product. Any such differences, in turn, are likely to affect the observed clinical effectiveness, drug survival, and safety.
In light of the uncertainty regarding the "real world similarity" of biosimilars, the aims of this study were to describe the uptake of infliximab and etanercept biosimilars for the treatment of rheumatic diseases in a setting without nation-wide forced switching, and to describe and compare the characteristics of patients starting a biosimilar or the originator product in this context.
Patients and Methods

2_1. Setting
Sweden is a Scandinavian country with 10 million inhabitants. The prevalence of rheumatoid arthritis (RA) in Sweden is around 0.7% [5, 6] while the combined prevalence of ankylosing spondylitis (AS), psoriatic arthritis (PsA) and other spondyloarthropathy (SpA) is around half that of RA. [7, 8] Swedish health-care is tax-funded and offers universal access. Regional economical agreements for pricing has resulted in geographical differences in choice of first-line biologics. For drugs administered at healthcare units (e.g. infliximab) regional economical agreements for pricing and recommendation of preferred drugs exist in Sweden, while for drugs on prescription to pharmacies (e.g. etanercept) such agreements are not allowed.
In contrast to other countries in which switching from originator to biosimilar has been mandatory and forced, Swedish health authorities have not instituted any mandatory switching.
Instead, the ultimate decision to treat with biologics (and, if so, with originator or biosimilar) resides with the treating physician. Guidelines by the Swedish Society for Rheumatology (SRF) initially issued a cautious approach to biosimilars, but once clinically available, switching from originator product to biosimilar has been endorsed for (informed) patients in stable remission or with a stable low disease activity. The Swedish Rheumatology Quality Register (SRQ) was started in 1995, and the estimated coverage for bDMARD-treated patients is 95% for RA and 86% for AS. [9] 2_2. Study population 
2_3. Patient characteristics
In SRQ, we identified information on age at start of treatment, gender, region of residence, disease characteristics, bDMARD treatment history, and vital status.
2_4. Statistical analysis
Differences between initiators of originators and biosimilars regarding demographics, previous treatment, and disease characteristics were tabulated using medians and percentages. Patients were stratified according to treatment (originator vs. biosimilar) and according to line of therapy: (i) bDMARD-naïve patients, (ii) patients switching from the originator to its biosimilar (non-medical switchers), and (iii) patients starting a biosimilar within six months after discontinuing (for any reason) a previous bDMARD of another type.
To assess differences between patients who started the originator vs. its biosimilar, we used multivariable linear regression, with bootstrapped 95% confidence intervals (CIs) to account for the skewed distribution of most outcomes. Models for age, gender, indication, and baseline disease characteristics were mutually adjusted, and additionally adjusted for geographical region.
For non-medical switchers, there was no readily available comparator group. Instead, we matched each patient in the non-medical switch group to five patients who, at the time of the index patient's switch, were still on the originator product. To allow identification of differences between the originator and the biosimilar users, no other factors were considered for the matching. Among bDMARD-naïve patients starting infliximab or etanercept, and among patients who switched to a biosimilar from a bDMARD other than the originator product, multivariable adjusted models did not demonstrate any significant differences between those starting an originator vs. its biosimilar (Appendix Table A1 and A2). We did however observe regional differences, more pronounced for infliximab than for etanercept, with some clinics showing strong preferences for either the biosimilar or the originator product (Appendix Table A3 ).
Results
Between
For non-medical switchers, we detected no significant differences comparing biosimilar initiators to their matched originator-product references individuals, except that non-medical switches had a shorter time on originator product (only etanercept), higher CRP levels (only infliximab) and higher concomitant use of methotrexate (both infliximab and etanercept) and NSAIDs (only infliximab) ( Table 1) .
Discussion
This study describes the uptake and system-level effects of introducing biosimilars into a setting with no forced switch, Swedish Rheumatology. Our results suggest that the introduction of biosimilars not only replaced part of the market of their originator products, but also may have contributed to an increase in the overall use of bDMARDs. Despite clear price differences between originator and biosimilar, the uptake of the latter was moderate, yet faster for the second biosimilar introduced (etanercept) than for the first (infliximab). Besides regional pricing agreements for infliximab that may have negatively impacted the economic incentive to switch, discussions of increased immunogenicity for infliximab, [10] and being the first biosimilar on the market, might explain the slower rate of non-medical switch. Small, or no, differences were observed in disease characteristics between patients starting the originator or the biosimilar, after stratification by line of therapy.
This study has several strengths. The SRQ is a large register with high coverage [9] and extensive information on patient characteristics and disease history. In contrast to for instance Denmark, [4] non-medical switch in Sweden has not been mandatory at the national level, thus allowing us to make comparisons between patients selected for originator or biosimilar treatment, both in the context of new-starters and in the context of non-medical switchers.
A limitation of this study was the assessment of disease characteristics; information was not always available at start of the treatment/switch. Therefore, we collected covariate information from the visit closest to the start of the treatment among all the visits that occurred between 90 days prior and 30 days after the prescription. However, for non-medical switchers and their comparators we retrieved information on disease characteristics at the last recorded visit ever, since the patients stable on drug are seen less often by the rheumatologist. The reported results cannot be generalized to other countries since we cannot assume that the strategy adopted by Sweden of a non-mandatory switch would have the same effects in other countries. A different purchasing systems of biopharmaceuticals and a different approach to the biosimilar by doctor and patients could lead to a completely different situation, in which the uptake of the biosimilars and the influence on the overall number of bDMARDs might differ.
Conclusions
In this first assessment of the uptake of biosimilars in Sweden, we observed effects beyond simple replacement of the originator product. Non-medical switch did not seem dependent on key disease-or treatment characteristics. It will now be an important task to assess whether comorbidities, or contextual factors differ between originators and their biosimilars and how they affect drug survival and treatment outcomes. 
